Given that one third of the world's population is infected with tuberculosis (TB), there is perhaps no bigger infectious disease global health threat than TB. This threat is compounded by the increasing prevalence of multi-drug resistant TB.
TGen is a global leader in development of next generation technologies for accurately detecting and monitoring drug resistance in tuberculosis. This work has resulted not only in new diagnostic tools that are now being validated in low- and middle-income countries, but also in advanced research tools that are being used to more fully comprehend the evolution of drug resistance in the patient's lung.
TGen is also helping to build the global knowledge base on the TB genome, by sequencing over 8,000 strains of TB from over 20 countries. Partnering with global health leaders in Africa, Asia, South America, and Europe, TGen researchers have helped pave the way to a new understanding of when and how resistance starts, providing a path towards earlier detection of resistance and giving physicians a personalized medicine approach to treating their patients.